According to Accelerate Diagnostics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.112071. At the end of 2022 the company had a P/E ratio of -0.0931.
Year | P/E ratio | Change |
---|---|---|
2022 | -0.0931 | -77.36% |
2021 | -0.4110 | -24.09% |
2020 | -0.5414 | -50.66% |
2019 | -1.10 | 54.59% |
2018 | -0.7099 | -68.03% |
2017 | -2.22 | 38.04% |
2016 | -1.61 | -24.4% |
2015 | -2.13 | -21.28% |
2014 | -2.70 | -6.95% |
2013 | -2.90 | 231.56% |
2012 | -0.8761 | -42.08% |
2011 | -1.51 | -269.58% |
2010 | 0.8919 | -195.56% |
2009 | -0.9333 | -43.19% |
2008 | -1.64 | -32.58% |
2007 | -2.44 | 228.97% |
2006 | -0.7407 | -41.52% |
2005 | -1.27 | -39.68% |
2004 | -2.10 | 52.73% |
2003 | -1.38 | -62.07% |
2002 | -3.63 | 274.41% |
2001 | -0.9682 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Thermo Fisher Scientific TMO | 38.8 | -34,727.16% | ๐บ๐ธ USA |
Becton Dickinson BDX | 42.6 | -38,090.74% | ๐บ๐ธ USA |
PerkinElmer
PKI | 15.0 | -13,454.57% | ๐บ๐ธ USA |
Bruker BRKR | 34.6 | -30,968.38% | ๐บ๐ธ USA |
NanoString Technologies NSTG | -0.0297 | -73.46% | ๐บ๐ธ USA |
Bio-Rad Laboratories BIO | -51.4 | 45,739.16% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.